Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06183489

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)

A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Sponsor: Pfizer

Interventions Elranatamab

Updated 9 times since 2024 Last updated: Oct 16, 2024 Started: May 14, 2024 Primary completion: Jul 31, 2027 Completion: Jul 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Smoldering Multiple Myeloma and is currently actively recruiting participants. Pfizer leads this study, which shows 9 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Nov 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
Stichting European Myeloma Network

Data source: European Myeloma Network B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Bari, Italy , Bergamo, Italy , Florence, Italy , Genova, Italy , Helsinki, Finland , La Roche-sur-Yon, France , Lille, France , Maastricht, Netherlands , Meldola, Italy and 15 more locations